Fludiazepam, marketed under the brand name Erispan, is a potent benzodiazepine and 2ʹ-fluoro derivative of diazepam.
Refer to Difludiazepam.
It was originally developed by Hoffman-La Roche in the 1960s.
It is marketed in Japan and Taiwan. It exerts its pharmacological properties via enhancement of GABAergic inhibition.
Fludiazepam has 4 times more binding affinity for benzodiazepine receptors than diazepam. It possesses anxiolytic, anticonvulsant, sedative, hypnotic and skeletal muscle relaxant properties. Fludiazepam has been used recreationally.
Difludiazepam is a benzodiazepine derivative which is the 2′,6′-difluoro derivative of fludiazepam.
It was invented in the 1970s but was never marketed, and has been used as a research tool to help determine the shape and function of the GABAA receptors, at which it has an IC50 of 4.1nM.
Difludiazepam has subsequently been sold as a designer drug, and was first notified to the EMCDDA by Swedish authorities in 2017.